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Abstract
Background: Adoption of modern contraceptive methods after menstrual regulation (MR) is thought to reduce
subsequent unwanted pregnancy and abortion. Long-acting reversible contraceptives (LARCs) are highly effective at
reducing unintended pregnancy, but uptake in Bangladesh is low. Providing information on the most effective methods
of contraception increases uptake of more effective methods. This protocol describes a randomised controlled trial of an
intervention delivered by mobile phone designed to support post-MR contraceptive use in Bangladesh.
Methods: This is a multi-site single blind individual randomised controlled trial. At least 960 women undergoing MR
procedures at selected facilities will be recruited after their procedure by female research assistants. Women will be
randomised into the control or intervention group with a 1:1 ratio.
All participants will receive usual clinic care, including contraceptive counselling and the telephone number of
a non-toll-free call centre which provides counselling on MR and contraception. During the 4 months after their MR
procedure, intervention participants will be sent 11 recorded interactive voice messages to their mobile phone about
contraception with a focus on their chosen method and LARCs. Each message allows the participant to connect
directly to the call centre. The intervention is free to the user. The control group will receive no messages delivered by
mobile phone. All participants will be asked to complete an in-person questionnaire at recruitment and follow-up
questionnaires by telephone at 2 weeks, 4 months and 12 months after their MR. The primary outcome for the trial will
be self-reported LARC use 4 months post-MR. Secondary outcomes include LARC use at 2 weeks and 12 months post-
MR, use of any effective modern contraceptive method at 2 weeks, 4 months and 12 months post-MR, and contraceptive
discontinuation, contraceptive method switching, pregnancy, subsequent MR and experience of violence during the
12 month study period.
Discussion: Mobile phones offer a low-cost mechanism for providing individualised support to women with
contraception outside of the clinic setting. This study will provide information on the effects of such an intervention
among MR clients in Bangladesh.
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Background
Abortion is illegal in Bangladesh except to save the life
of a women, however ‘menstrual regulation’ (MR) is
allowed as an “interim method to establish a state of
non-pregnancy in a woman who is at risk of being preg-
nant” [1]. MR is legal when provided by a registered ser-
vice provider as a surgical procedure with manual
vacuum aspiration (MVA) up to 12 weeks from the last
menstrual period or as a medical procedure (menstrual
regulation with medication (MRM)) up to 9 weeks gesta-
tion using a combination regimen of mifepristone and
misoprostol [2, 3]. Economic, cultural and informational
barriers limit access to legal MR services and many
women still turn to illegal abortions which are often un-
safe, putting them at risk of harm [4–6]. MR and abor-
tion incidence can be estimated using facility and
population surveys, service numbers and key informant
interviews [6, 7]. In 2014, an estimated 430,000 MR pro-
cedures took place at health facilities in Bangladesh [8].
Use of modern contraception has the potential to avert
the majority of abortion related morbidity and mortality
around the world [9, 10]. In Bangladesh, 12% of cur-
rently married women aged 15–49 years have an unmet
need for family planning [11], this figure is slightly lower
than the average for Southern Asia (14%) [12]. The type
of contraceptives a woman uses has implications for un-
intended pregnancies: the contraceptive pill has a failure
rate of 8% in the first year of typical use, whereas the
most effective reversible methods of contraception, the
intra-uterine device (IUD) and the implant (termed
long-acting reversible contraceptives or LARCs), have
failure rates of between 0.05% and 0.8% in the first year
of use [13]. LARCs also have lower discontinuation rates
and higher user satisfaction than short-term methods
(such as the pill, condom, and injectable) [11, 13–15]. In
Bangladesh, 40% of condom users and 34% of pill users
discontinue their method within a year, the latter often
due to side effects or health concerns; however, the rate
of discontinuation for implant users is just 7% [11]. Des-
pite this, short-term methods dominate in Bangladesh,
in 2014 the method mix was as follows: 27.0% of mar-
ried women of reproductive age used the pill, 12.4% used
the injectable, 6.4% condoms, 1.7% the implant and 0.6%
the IUD [11]. A further 8.4% of women rely on natural
methods such as abstinence and withdrawal and 5.8%
use sterilisation [11]. Interventions have demonstrated
that removal of barriers to LARC use, such as know-
ledge gaps and cost, can increase uptake of these
methods [14, 16].
Interventions are needed to support continuation and
correct use of short-term methods and to address bar-
riers to use of LARCs and permanent methods of
contraception among Bangladeshi women at risk for un-
wanted pregnancy. MR clients are a key population to
target as they often want to delay or limit future preg-
nancies. The WHO recommends provision of post-
abortion family planning as an effective way of reducing
subsequent unwanted pregnancy and abortion [17].
Most facilities in Bangladesh offer post-MR family plan-
ning counselling and services however gaps remain: the
full range of contraceptive methods is not always avail-
able and counselling is often limited to the day of the
procedure as WHO does not currently recommend rou-
tine follow-up for MR cases [17, 18].
The fast, cheap and confidential communication of-
fered by mobile phones and their high and increasing
prevalence of ownership in developing countries makes
them a viable means of delivering sensitive information
to large populations. In contrast to counselling on the
day of an MR procedure, mobile-phone-based health
(mHealth) interventions can give women time to con-
sider their contraceptive options. At the time of proced-
ure, women’s focus may be on the MR rather than on
family planning; in Cambodia women have said they find
it difficult to make a decision on the day of procedure
[19]. Furthermore, women may want time to discuss
their family planning choices with their husband/partner
or other family members [19]. Use of mobile phones in
Bangladesh is high and increasing; in 2014, 89% of all
households reported having a mobile phone [11] making
it a good context for mHealth interventions. However
inequities remain; among 20–29 year olds, 90% of men
but just 54% of women have a phone [11].
A feasibility study conducted in Bangladesh in 2013
among 120 public sector MR and post abortion care cli-
ents randomly assigned 60 participants to receive one-
way short message service (SMS) messages reminding
them about contraception (Biswas K, Hossain A,
Chowdhury R, Andersen K, Sultana S, Shahidullah SM,
Pearson E: Using mHealth to Support Postabortion
Contraceptive Use: Results from a Feasibility Study in
Urban Bangladesh, Unpublished). The intervention was
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well received: 76% of women in the intervention group
reported they would sign up to the messages again and
93% said they felt the messages had helped them to use
contraception. Participants also expressed an interest in
speaking to a hotline counsellor, and half said they
would prefer automated calls to SMS messages as it
would be better for confidentiality.
Globally, some evaluations of mHealth interventions
have demonstrated that they can be effective in improv-
ing health behaviours and outcomes, but the evidence is
limited and outcomes are mixed [20, 21]. Findings sug-
gest that multifaceted approaches may be more effective
but further research is required to establish how to opti-
mise interventions [20]. Evidence for the effectiveness of
mHealth interventions aimed at improving contraceptive
use is limited and shows mixed results [22]. One trial fo-
cused on post-abortion contraception and found that
interactive voice messages linked to call centre counsel-
ling sent to abortion clients in Cambodia were successful
in increasing contraceptive use at 4 months but not at
12 months [16].
This trial aims to examine the effects of an intervention
delivered by mobile phone designed to support contracep-
tive use among public and private sector MR clients in
three divisions of Bangladesh. The trial hypothesis is that
the women who receive a multi-component mHealth
intervention will have higher rate of LARC use at 2 weeks,
4 months and 12 months post-MR, compared to women
who do not receive the mHealth intervention.
Methods/design
Trial design
The intervention will be evaluated using a multi-site,
single-blinded RCT. Participants are randomized to the
intervention (interactive voice messages that optionally
link to telephone counselling in addition to standard
care plus the call centre number) or control (standard
care plus call centre number) with a 1:1 ratio.
Study setting
Women will be recruited from Marie Stopes Bangladesh
(MSB) facilities and public sector facilities that are sup-
ported by Ipas Bangladesh. MSB operates 140 clinics that
offer sexual and reproductive health services including
family planning, post-abortion care (PAC) and MR across
the country. Ipas Bangladesh currently supports 82 govern-
ment and non-government Reproductive Health Services
Training and Education Programme (RHSTEP) facilities,
providing training on woman-centred MR, PAC and post-
abortion family planning for physicians and mid-level pro-
viders working in intervention clinics.
MSB and public-sector clinics supported by Ipas will
be eligible to participate if they are in Dhaka, Chittagong
or Sylhet Division, have an average monthly case load of
at least 20 MR clients and have no other intervention
studies underway. Eligible clinics will be stratified into
primary, secondary and tertiary levels to ensure repre-
sentation from all facility types as these facilities serve
different populations of women. Primary level clinics are
smaller clinics and are in rural and peri-urban areas.
Secondary clinics are larger clinics located in urban
areas; they provide a wider range of services and act as
referral points for the primary level clinics. Tertiary
clinics are hospitals located in large cities.
Seventeen sampling units of 19 participants will be se-
lected at random from the list of eligible facilities in each
strata using probability proportional to size based on
mean monthly client flow in the past 3 months. If re-
cruitment monitoring shows these clinics will not
achieve full recruitment within the specified time-frame
further clinics will be recruited. This will ensure 323 cli-
ents are recruited per strata, to allow between strata
comparison, yielding a total sample of 969.
Eligibility criteria
All women who meet the following inclusion criteria will
be eligible for participation: (1) received MR with MVA
or MRM from a participating clinic; (2) 18–49 years of
age; (3) did not receive general anaesthesia for their MR
procedure; (4) have a personal mobile telephone; (5)
consent to receiving voice messages about family plan-
ning on their phone; (6) don’t intend to become preg-
nant within the next 6 months and (7) don’t intend to
use (or for their partner to use) a permanent method of
contraception in the next 6 months.
Recruitment procedure
Participants will be recruited using the following steps,
stages 1–4 are standard in the MR services provided at
all MSB clinics and government facilities supported by
Ipas. 1. MR is discussed with the client, the type of MR
procedure is chosen and family planning is introduced, if
a client wants an IUD fitted during the MVA procedure,
this is agreed now. 2. The MVA procedure takes place
or mifepristone (an oral pregnancy termination medica-
tion, also called RU486) is administered. 3. MVA clients
can visit a recovery room. 4. Post-MR counselling is pro-
vided, including further discussion of family planning.
Contraceptive method(s) are provided if desired. MVA
clients can start any contraceptive method on the day of
MR procedure, MRM clients can start any method apart
from an IUD or female sterilization which can be pro-
vided after non-pregnancy has been established. 5. If the
client is interested, she will be referred to a female re-
search assistant (RA) who will explain the study and
enrol her if she wishes. Alternatively, clients can return
to the clinic within 2 days of their MR procedure for fur-
ther information and enrolment. 6. Women who choose
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to participate will be asked to sign or thumbprint an in-
formed consent form. Consent forms will also be signed
by the interviewer and by a witness chosen by the client.
No financial incentives will be received for recruiting
participants. Women participating in the study will receive
300 taka (approximately US$3.83 in February 2016) in
cash at the time of enrolment as a token of appreciation
for their time. They will receive an additional 100 taka for
the short interview at 2 weeks post-MR and 200 taka for
each of the longer follow-up interviews (at four and
12 months post-MR) using phone credit. To reduce loss
to follow up, participants will be asked for any alternative
phone numbers that can be used to contact them to con-
duct follow up interviews if we cannot reach them on
their primary number.
To ensure the potential participants fully understands
the intervention and to verify that it is not likely to put
her at risk of harm, an example message will be played
on the either the client’s or RA’s phone during recruit-
ment (prior to randomisation) and the RA will explain
how to use the interactive functions. After the message
has been heard, the RA will ask the client whether she is
happy to receive this type of message on her phone and
what would happen if their husband, partner or some-
one else like her in-laws or other family member heard
the message. If any concerns are raised the client will be
advised not to participate and if necessary referred for
further support.
Randomisation
The allocation sequence will be generated remotely by a
researcher at an independent research institute prior to
the start of recruitment in Excel using the formula
“=RANDBETWEEN(1, 2)”. The list will be password pro-
tected and only the independent researcher and a London
based non-researcher (as a back-up) will have access to it.
After each enrolment, RAs will send a unique participant
ID and the participant’s phone number, family planning
method and preferred message time slot to a technical of-
ficer based at the Marie Stopes Bangladesh (MSB) head
office in Dhaka via a secure app. At the end of each day,
the technical officer will email the IDs of new participants
to the independent researcher for randomisation. The in-
dependent researcher will allocate participants to either
the intervention or control group using the pre-generated
randomisation list. On receiving the allocations from the
independent researcher, the technical officer will initiate
the intervention for those participants in the intervention
group. This method will ensure allocations are concealed
from the RAs recruiting clients and to service providers.
Allocations will be concealed from RAs conducting the
follow-up interviews during collection of data on the pri-
mary outcome and will also be concealed from one data
analyst. Allocations are expected to be assigned within 2
days of enrolment. It will not be possible to blind partici-
pants to their allocation group. RAs conducting recruit-
ment will not be un-blinded during the trial period.
Intervention
The intervention was designed in 2015 based on 24 in-depth
interviews with MR clients [23], literature reviews on barriers
to and predictors of contraceptive use in Bangladesh, global
evidence for the effectiveness of interventions delivered by
mobile phone and behavioural theory [24]. Draft message
content was tested with the target group. Full details of the
development process will be reported elsewhere.
Each participant will be sent a series of 11 automated,
interactive voice messages sent to their mobile phone over
a 4-month period, starting within a week of the MR pro-
cedure. Messages will be sent weekly for the first 6 weeks
and fortnightly for the following 8 weeks. The recorded
messages, which are free to receive, start playing when the
phone is answered and are delivered through a secure on-
line platform from ‘I Am Digital’ in Dhaka. If the call is not
answered it is re-sent after 30 min and again after another
30 min. At the end of each of the 11 messages, the recipi-
ent can press keys one to five to select one of the following
options: (1) repeat the message; (2) listen to one or more of
seven additional messages, one about each modern method
of contraception (condoms, pills, injectable, implant, IUD,
male and female sterilization); (3) speak to a call centre
counsellor; (4) report that they are fine and don’t need fur-
ther information today or (5) opt out from receiving further
messages. At recruitment, the participant is asked to select
one of five time slots for receiving the messages. The con-
tent of the 11 messages is tailored to the individual’s chosen
method as follows: the method of contraception received at
the clinic is used to allocate participants to one of six mes-
sage groups: no method users, condom users, pill users, in-
jectable users, implant users and IUD users. Seven core
messages will be sent to all participants reminding them of
the benefits of using contraception, addressing key barriers
such as fear of infertility and addressing information gaps,
particularly around LARC and permanent methods. The
remaining four messages will be specific to the method
group for example, pill users will receive the seven core
messages plus four messages tailored to supporting pill use.
For current contraceptive users, the tailored messages pro-
vide information and support for continuation and correct
use of their chosen method, they also aim to promote safe-
switching among women who are not happy with their
method. The tailored messages sent to non-users are de-
signed to encourage uptake of contraception. Women are
reminded at recruitment and in the messages to inform the
call centre counsellor if they switch contraceptive methods.
The messages do not mention MR or refer to the partici-
pant’s clinic visit to prevent their MR status being disclosed
should someone else answer or overhear the call.
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The call centre is operated by three paramedics who
have received training on MR, contraceptives and counsel-
ling. Women who contact the call centre are referred to
MSB clinics or government facilities for services if needed.
Both control and intervention groups will receive
post-MR counselling provided at the facility and infor-
mation about the call centre which can be called at the
cost of a standard call to a mobile phone. Women
assigned to the control group will not receive any inter-
vention messages.
Data collection
Data collection tools will be developed in English then
translated into and administered in Bangla. Where pos-
sible we will use or adapt existing tools including ques-
tions from the Bangladesh Demographic Health Survey
[25]. On the first day of recruitment, data on the family
planning services available at participating facilities will
be collected from the facility manager or MR provider
using a questionnaire administered by an RA (following
informed consent). Study participants will be inter-
viewed by the recruiting RA after enrolment to collect
data on demographics (poverty level will be measured
using the Progress out of Poverty Index (PPI)), repro-
ductive history and intentions, the current MR and any
family planning counselling and methods received,
household decision making, experience of violence, type
and frequency of mobile phone usage, contact phone
number and preferred time of day to receive messages
and to be contacted for follow up interviews.
Female RAs based at the MSB head office will adminis-
ter follow-up questionnaires by telephone. The 2-week
interview lasting approximately 5 min will ask about
current contraceptive use. Changes in contraceptive
method among intervention participant will be made in
the online platform administering the messages. The 4-
month and 12-month questionnaires will last approxi-
mately 15 min and will ask about marital status, fertility
intentions, experience of violence, contraceptive use in the
preceding months/weeks, any pregnancies or MR proce-
dures, contraceptive discontinuation and reasons for stop-
ping a method. Information on side effects will be collected
where it led to discontinuation of a method. The 4 and
12 month follow up survey questions will be the same ex-
cept that the time frame for some questions will differ and
the 4-month survey will include measurement of hypothe-
sised intermediate outcomes and questions to assess use of
and satisfaction with the intervention and any related priv-
acy concerns. Questions on the outcome will be asked at
the start of the interview, prior to questions about the
intervention.
All contraceptive use and non-use since baseline will
be recorded using a modified version of the
Demographic and Health Survey contraceptive calendar
[25]. Participants will be asked at recruitment whether
they consent to the study team accessing their clinic re-
cords to verify reports of MR procedures and LARC in-
sertions or removals.
To ensure high participation in follow-up interviews we
will collect a range of contact data for each participant
and will ask participants to inform us if their contact de-
tails change. The reimbursements at each follow-up inter-
view are also expected to increase participant retention.
Use of the intervention
Data on use of the intervention such as whether
recorded voice messages are listened to and whether cli-
ents interact with the messages will be generated by the
mHealth platform. Calls to the call centre will be moni-
tored; call centre operators will complete a standard
form for every caller to collect basic information on who
the caller is (participant themselves, husband, friend
etc.) and the reason or reasons for the call. A small
number of calls will be audio recorded.
Outcome measures
Primary and secondary outcomes and the methods of
data collection are summarised in Table 1.
Primary outcome
The primary outcome measure is use of a LARC (IUD or
sub-dermal implant) at 4 months post-MR. Participants
will be considered ‘LARC users’ if they report having a
sub-dermal implant or IUD inserted at the 4-month fol-
low up interview. The 4-month time point was selected to
enable us to establish any effect of the intervention on
continuation of the injection (effective for 3 months) and
pills (clinics usually dispense 3 months-worth of pills).
Secondary outcomes
Secondary outcome measures include current use of any
effective modern contraceptive method at 2 weeks, 4
and 12 months post MR. We define modern contracep-
tive methods according to the WHO as those associated
with <10% 12 month pregnancy rates [13]. These will be
measured as having had or having a partner who has
had sterilization, currently have a sub-dermal implant or
an IUD inserted, have received the injection in the last 3
months, currently using the contraceptive pill and
reporting that they always or usually take the pill on
time. Further secondary outcomes are self-reported
pregnancy at the time of the four and 12 month inter-
views, having had an MR since enrolment into the study
and having experienced violence since enrolment. Data
from the contraceptive calendar will be used to estimate
a point prevalence of contraceptive use at any given time
and contraceptive discontinuation rates.
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Hypothesized intermediate outcomes
At 4-months, data will be collected on the following hy-
pothesized intermediate outcomes: satisfaction with fam-
ily planning method, frequency of communication about
family planning with husband and with in-laws, know-
ledge and attitudes towards family planning and self-
efficacy to use contraception.
Dose
The effect of the dose of the intervention on the primary
outcome will be examined using self-reported informa-
tion on intervention use (listened to none, some or all of
the messages), spoke to a call centre counsellor (yes/no).
Sample size
Sample size calculations were based on the primary out-
come: LARC use 4 months after the MR procedure. Based
on approximately 28,000 MR procedures conducted be-
tween November 2011 and June 2013 in government facil-
ities supported by Ipas and approximately 16,500 in MSB
clinics between October and December 2013, 7.0% of
women are expected to select an IUD as their post-MR
contraceptive method and 2.4% an implant, resulting in an
expected 9.4% LARC uptake at baseline. A similar
mHealth trial in Cambodia saw LARC use at 4 months in-
crease from 9% to 29% with receipt of the intervention.
Given the low cost of sending automated phone messages,
a smaller increase may be programmatically important.
To detect an absolute increase in LARC use of 7%, from
9.4% in the control group to 16.4% in the intervention
group (a relative risk of 1.74), at four-month follow-up
with a 0.05 significance level and 80% power, and assum-
ing equal numbers of women in intervention and control
groups the study needs a minimum of 714 participants.
We increased this to a minimum of 960 to allow for 25%
loss to follow-up (Fig. 1).
Data management
The questionnaires will use anonymous ID numbers to
identify respondents in the analysis. They will be com-
posed of one digit to identify the clinic type (MSB/Ipas),
followed by two digits for the facility code followed by a
unique client identifier, composed of the day, month,
staff member code and client number. An example of
this could be M 01 2804 02 03. M indicates it is an MSB
facility, 01 is the facility code. Two thousand eight hun-
dred four is the date of the enrolment, 02 indicates the
staff member code within the clinic and 03 indicates that
it is the 3rd client enrolled on that day.
Study consent forms and baseline questionnaires will be
photocopied at the facility. One copy will be posted to a
central office for entry and storage, the other copy will be
stored securely at the facility or in a locked location at the
home of the research assistant until it can be collected in
person by the research team. Two-week, 4 and 12 month
questionnaires will be stored securely in a locked cabinet at
MSB and the data entry company head offices in Dhaka.
To protect women’s confidentiality, data will be recorded
using numeric study identifiers, and all data (both hard
copy and electronic) will be stored under the study identi-
fiers and kept in locked file cabinets and password pro-
tected files, respectively. Data entry will be done in
Microsoft Access by an external data entry specialist, and at
least 10% will be double-entered. After entry, data will be
checked for consistency and completeness. Data on contra-
ceptive use will be cross-checked between time points, for
example contraceptive calendar data collected at 4 months
will be cross checked with baseline and 2-week data. Data
will be checked for incompatible responses, for example be-
ing pregnant and using a method of contraception at
follow-up. The data will be cleaned, analysed, and findings
will be written up, by the principle investigators and re-
searchers at Marie Stopes, Ipas and The London School of
Hygiene and Tropical Medicine. Only the researchers con-
ducting follow up surveys and those entering and checking
Table 1 Outcome variables and analysis methods
Outcome Questionnaire Outcome measure Method of analysis
Primary
LARC use Baseline, 2-week, 4-
month & 12-month
Self-reported (binary) Logistic regression
Secondary
Use of any modern
contraceptive
Baseline, 2-week,
4-month & 12-month
Self-reported (binary) Logistic regression
Pregnancy 4-month & 12-month Self-reported (binary) Logistic regression
MR 4-month & 12-month Self-reported (binary) Logistic regression
Discontinuation/
Method switching
2 week, 4-month & 12-
month
Self-reported (#of times, continuous) Log Rank test Kaplan
Meier Curves
Experience of violence 4-month and 12 month Self-reported (binary) Logistic regression
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data will have access to participant contact details. Audio
recordings of calls to the call centre will be transcribed and
translated into English.
Training and monitoring
Research Assistants enrolling participants into the study
and collecting baseline data will attend a 5-day training in
Dhaka led by one international and one local investigator.
Five supervisors will be trained to conduct supervision
visits to ensure study protocols are being followed. Super-
visors will be given a checklist to complete at each visit.
Regular monitoring visits will be made by the study man-
ager during enrolment and data collection to ensure study
protocols are being followed and to identify any problems
with recruitment or data collection. If necessary, further
guidance or training will be provided to data collectors.
Research Assistants conducting follow-up surveys will re-
ceive up to 5 days training (dependent on whether they
have previous involvement in the study). Follow up data
collection will be monitored by the study manager during
daily de-briefs.
No data monitoring committee will be established for
this trial as the likely risks to participants of receiving an
mHealth intervention are known to be minimal. All ad-
verse events reported to the study team during follow up
surveys or via calls to the study or call centre numbers will
be reported by the study manager to the principal investi-
gator within 1 week of their occurrence. The response will
be agreed with the other study investigators and where ap-
propriate reported to the ethical committees.
Fig. 1 Study design and participant timeline
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The protocol and intervention were reviewed by an in-
country advisory committee who will meet intermittently
to review progress and give input. The committee includes
the Director of Primary Health Care and Director of
Continued Medical Education at the Directorate General
of Health Services; the Director of Maternal and Child
Health services and the Director of Information,
Education and Motivation at the Directorate General of
Family Planning; Executive Director, Reproductive Health
Services, Training and Education Programme (a non-
governmental organisation working in Government of
Bangladesh Hospitals); Director, Bangladesh Association
for Prevention of Septic Abortion; President, Obstetric
and Gynaecological Society of Bangladesh; Country
Director, Population Council; Chief Executive Officer,
Bangladesh Centre for Communication Programme;
Senior Director, Marie Stopes Bangladesh; Country
Director, Ipas Bangladesh.
Data analysis
We will adhere to the CONSORT guidelines for report-
ing RCT conduct and outcomes. Intention-to-treat prin-
ciples will be used for primary outcome analysis,
meaning all participants will be analysed according to
the arm to which they were randomised. We will investi-
gate the patterns of missing data, and will report any
treatment group imbalances between those who do and
do not complete the study.
The primary analysis, using multiple imputation to
handle missing data (as detailed below), will be a logistic
regression of 4-month LARC use on treatment and base-
line use. For the primary analysis, we assume data are
missing at random, given treatment group, 2-week and
baseline LARC use, baseline socio-economic status
(SES) and age. Under this assumption, multiple imput-
ation of missing 4-month data will be performed separ-
ately for the two intervention groups, by full conditional
specification, using the following variables: baseline, 2-
week and 4-month LARC use, together with auxiliary
variables, baseline SES and age. The multiple imputation
procedure will also impute any missing baseline data
(under the same assumption). One hundred imputed
datasets will be created, and the imputation process will
be checked for convergence and perfect prediction.
The primary analysis will be validated by an analysis
under the slightly stronger assumption that data are
missing at random, given treatment group, baseline
LARC use, baseline SES and age. This can be achieved
with a logistic regression of 4 month LARC use on base-
line LARC use, intervention group, baseline SES and
age. Robustness of inference from the primary analysis
to the missing at random assumption will be explored
using the “δ -method” for information-anchored sensi-
tivity analysis [26].
Keeping the information in the data constant, this
method allows us to explore the robustness of our con-
clusions about treatment to the missing at random as-
sumption (MAR). In this study, MAR assumes that —
among patients in the same treatment group, with simi-
lar baseline data and similar early follow-up — the odds
of LARC use at the end is the same whether or not their
data are missing. This assumption is untestable, so the
“δ -method” explores how the conclusions vary as — still
among patients in the same treatment group, with simi-
lar baseline data and similar early follow-up — the odds
of LARC use at the end differs by δ between patients
with observed and missing data.
Contraceptive discontinuation rates will be estimated
over the one-year project period using Kaplan-Meier
curves, overall and by family planning method. The log-
rank test will be used to test for differences in discontinu-
ation rates between methods. Table 1 summarizes the
method of analysis for the primary and secondary out-
comes. We will use Stata to conduct data analysis [24].
Data on use of the messages and details of calls made to
the call centre will be analysed descriptively. Sub group
analysis will be conducted to explore whether the inter-
vention effect varies according to age, education, SES, type
of MR procedure (medical vs surgical), experience of
violence in the last year (yes/no), and on who makes deci-
sions about whether the participant uses contraception
(self/self and one or more other person/other person).
Transcripts from the calls to the call centre will be
analysed qualitatively to examine the type of information
and/or support the counsellors provide to enable a more
detailed description of the intervention.
Dissemination policy
Findings will be shared with stakeholders through formal
reports and presentations at the local and national levels,
and more broadly through peer-reviewed publications
and international conference presentations. The re-
searchers will present the findings to the advisory com-
mittee prior to wider dissemination.
Authorship eligibility will be dependent on substantial
contributions to planning, implementing, analysing or
drafting of findings. The de-identified dataset will be made
publicly available following publication of trial results.
Discussion
Closing knowledge gaps about effective methods of contra-
ception is vital to supporting women’s choice and uptake of
effective post-MR contraception. There have been few high
quality evaluations of mHealth interventions designed to
increase contraceptive use and continuation, particularly in
low and middle income settings, and only one, MOTIF in
Cambodia, has focused on a post-abortion population [22].
MOTIF also comprised an interactive voice message sent
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to mobile phones but used one standard message sent to all
participants and relied heavily on call centre counsellors
who provided personalised support and appointment book-
ings [16]. This one-to-one personalised support may be key
to the intervention’s success but the cost of counselling
could be a barrier to scale up. In the Bangladesh interven-
tion counselling is still available however participants are
first directed to automated content that aims to address
some of the most commonly reported barriers to uptake
and continuation of contraception in this context. It is im-
portant to explore whether automated content can reduce
cost by replacing counsellor time but remain effective. This
evaluation will provide much-needed information on the
effectiveness of an mHealth to inform women about effect-
ive methods of contraception, and facilitate adoption of
these methods in the post-MR period. mHealth has great
promise as a low-cost intervention, and this trial will pro-
duce results that can inform programs and policies in
Bangladesh and elsewhere.
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